Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fareed

Showing results (171-180 of 384) with videos related to

Pageof 39
Sort By:
Seminars in Thrombosis and Hemostasis|January 1, 1996
Are the available low-molecular-weight heparin preparations the same?J Fareed, W Jeske, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021O Iqbal, W Jeske, D Hoppensteadt, et al.
Acta Orthopaedica Belgica|January 29, 1999
Role of neuropeptides in pathogenesis of reflex sympathetic dystrophyS J Blair, M Chinthagada, D Hoppenstehdt, et al.
The Canadian Journal of Cardiology|October 21, 1998
Low molecular weight heparins: are they different?J Fareed, D Hoppensteadt, W Jeske, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1983
Synthetic peptide substrates in hemostatic testingJ Fareed, H L Messmore, J M Walenga, et al.
Haemostasis|January 1, 1991
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudinJ Fareed, J M Walenga, R Pifarre, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1985
A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractionsJ Fareed, A Kumar, A Rock, et al.
Mediators of Inflammation|January 1, 1993
Heparan sulphate inhibition of cell proliferation induced by TGFbeta and PDGFL E Silber, J M Walenga, J Fareed, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Coagulant versus amidolytic properties of human and bovine thrombins: implications in standardization and diagnostic usageJ Fareed, J M Walenga, L G Svendsen, et al.
Annals of the New York Academy of Sciences|January 1, 1989
Biochemical and pharmacologic inequivalence of low molecular weight heparinsJ Fareed, J M Walenga, D Hoppensteadt, et al.
Pageof 39

Showing results (171-180 of 384) with videos related to

Sort By:
Pageof 39
Seminars in Thrombosis and Hemostasis|January 1, 1996
Are the available low-molecular-weight heparin preparations the same?J Fareed, W Jeske, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021O Iqbal, W Jeske, D Hoppensteadt, et al.
Acta Orthopaedica Belgica|January 29, 1999
Role of neuropeptides in pathogenesis of reflex sympathetic dystrophyS J Blair, M Chinthagada, D Hoppenstehdt, et al.
The Canadian Journal of Cardiology|October 21, 1998
Low molecular weight heparins: are they different?J Fareed, D Hoppensteadt, W Jeske, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1983
Synthetic peptide substrates in hemostatic testingJ Fareed, H L Messmore, J M Walenga, et al.
Haemostasis|January 1, 1991
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudinJ Fareed, J M Walenga, R Pifarre, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1985
A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractionsJ Fareed, A Kumar, A Rock, et al.
Mediators of Inflammation|January 1, 1993
Heparan sulphate inhibition of cell proliferation induced by TGFbeta and PDGFL E Silber, J M Walenga, J Fareed, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1986
Coagulant versus amidolytic properties of human and bovine thrombins: implications in standardization and diagnostic usageJ Fareed, J M Walenga, L G Svendsen, et al.
Annals of the New York Academy of Sciences|January 1, 1989
Biochemical and pharmacologic inequivalence of low molecular weight heparinsJ Fareed, J M Walenga, D Hoppensteadt, et al.
Pageof 39